Loading page
Loading page
Loading substance route
Bromo-DragonFLY demonstrates remarkable potency and highly variable batch strength. Material circulating prior to 2006 was considerably more potent than subsequent supplies. Individual sensitivity varies significantly; exercise extreme caution with any unfamiliar batch.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Bromo-DragonFLY is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
Bromo-DragonFLY appears to have fairly high toxicity for humans relative to its active dose range. Typical doses are 100-1000 μg orally, but a death has been reported at approximately 700 μg. At least five deaths have been documented across Norway, Sweden, Denmark, Finland, and the United States. A mislabeling incident where Bromo-DragonFLY was sold as 2C-B-FLY (approximately 20 times less potent by weight) contributed to several lethal overdoses. Synthesis impurities in implicated batches may have also contributed to toxicity.
Severe overdose causes extreme, prolonged vasoconstriction that can lead to dangerous hypertension, tissue necrosis of extremities, gangrene, and potentially limb amputation; elevated heart rate and blood pressure occur during typical intoxication but serious vascular damage is associated with massive overdoses.
Overdose effects include bizarre, delusional, and sometimes violent behavior, along with terrifying hallucinations, severe confusion, and amnesia. The extremely long duration of effects and the substance's abnormally prolonged presence in the body may increase psychological distress. Users may become severely agitated and unable to communicate.
Seizures and convulsions have been reported as side effects, particularly in overdose situations. Multiple fatalities involved seizures as part of the clinical presentation, including cases where individuals experienced seizures, vomited blood, and suffered terrifying hallucinations before death.
Bromo-DragonFLY emerged from academic research conducted at Purdue University during the mid-1990s, where it was initially developed as a novel chemical tool for studying serotonin receptor binding in rat brain tissue. The compound was formally synthesized and characterized in 1998 by Matthew…
Not scheduled under the UN Convention on Psychotropic Substances 1971
Listed under Schedule 9 of the Poisons Standard nationally since February 2009, making possession, production, and sale illegal. Additionally added to Schedule 2 of the Queensland Drugs Misuse Regulation 1987 as of September 9, 2011.
Banned on December 3, 2007, following recommendations from the Danish Health Ministry. Classified as a dangerous narcotic substance, prohibiting possession, manufacture, importation, supply, and usage.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as a derivative of 2-phenethylamine. Production and sale are prohibited; however, possession and import are not penalized when intended solely for personal consumption.
Listed on the Norwegian narcotics list and controlled under the 'Derivatbestemmelsen,' an analogue act-type provision that regulates structurally similar compounds.
Added as an illegal substance under Law 143/2000 on February 10, 2010. Possession, production, and sale are prohibited.
Legal status remains ambiguous. May potentially fall under Verzeichnis E point 130 or Buchstabe C of controlled substances regulations due to structural relationships with controlled amphetamine derivatives, though the exact scope of these definitions is unclear.
Not explicitly named in the Misuse of Drugs Act 1971. Coverage under the phenylethylamine Class A catch-all clause is disputed due to its benzodifuran structure. Definitively covered by the Psychoactive Substances Act 2016 when sold or traded for human consumption.
Added to Schedule III of the Controlled Drugs and Substances Act on October 12, 2016, under the broad classification of '2C-phenethylamines and their salts, derivatives, isomers and salts of derivatives and isomers' which encompasses compounds with a 2,5-dimethoxyphenethylamine core.
Classified as an illegal designer drug as of March 12, 2012. Added to the national list of controlled substances.
Designated as a controlled substance effective August 19, 2015.
Not currently scheduled or controlled under Polish drug legislation.
Listed as a Schedule IV narcotic substance as of January 3, 2008, under Medical Products Agency regulation LVFS 2007:14. Previously classified as a 'health hazard' on July 15, 2007, under SFS 2007:600, which prohibited sale, purchase, retail, and possession.
Classified as a controlled drug. Possession, production, supply, and importation are prohibited.
Not scheduled at the federal level. The Federal Analogue Act may apply if sold for human consumption due to structural similarities with DOB and 2C-B. Listed as a Schedule I controlled substance in the state of Oklahoma.
12 sources cited